WO2023078073A1 - 一种包含孕激素的新型口服制剂及制备方法和应用 - Google Patents

一种包含孕激素的新型口服制剂及制备方法和应用 Download PDF

Info

Publication number
WO2023078073A1
WO2023078073A1 PCT/CN2022/125665 CN2022125665W WO2023078073A1 WO 2023078073 A1 WO2023078073 A1 WO 2023078073A1 CN 2022125665 W CN2022125665 W CN 2022125665W WO 2023078073 A1 WO2023078073 A1 WO 2023078073A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral formulation
propylene glycol
oral
monocaprylate
preparation
Prior art date
Application number
PCT/CN2022/125665
Other languages
English (en)
French (fr)
Inventor
杜新
李杉杉
杜涛
Original Assignee
深圳埃格林医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳埃格林医药有限公司 filed Critical 深圳埃格林医药有限公司
Publication of WO2023078073A1 publication Critical patent/WO2023078073A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the application belongs to the field of pharmacy, and specifically, the application provides a novel oral preparation containing progesterone, its preparation method and application, and the preparation does not contain or only contains low levels of benzyl benzoate.
  • Progestogens include progesterone, norethindrone, norethindrone, 17- ⁇ hydroxyprogesterone, etc., which have a variety of physiological functions in the human body.
  • 17- ⁇ hydroxyprogesterone has been used for contraception and treatment of miscarriage , Irregular menstruation, uterine bleeding, breast cancer and other diseases.
  • 17-alpha hydroxyprogesterone caproate has the effect of treating cytokine storm syndrome, and has applied for a patent on this.
  • Oral preparations are obviously superior to injection and other dosage forms in terms of convenience and compliance.
  • the applicant previously cooperated with other subjects to develop 17- ⁇ hydroxyprogesterone caproate oral preparations and applied for a patent.
  • This preparation has good oral availability and stability. But this preparation takes benzyl benzoate as the main solvent component, and the safety performance of benzyl benzoate to the human body has not been clearly studied.
  • JECFA Joint Expert Committee on Food Additives
  • ADI Acceptable Daily Intake
  • the applicant screened a large number of excipients in terms of basic properties and safety, and designed oral preparations with high safety, good stability, dissolution performance and bioavailability.
  • the present application provides an oral preparation containing progestin, characterized in that the oral preparation does not contain or only contains a low level of benzyl benzoate.
  • progestin is 17- ⁇ hydroxyprogesterone caproate.
  • the weight percentage of benzyl benzoate in the oral preparation is lower than 8%; preferably, lower than 7%; more preferably, lower than 6%; more preferably, lower than 5%.
  • the weight percentage of benzyl benzoate in the oral preparation is lower than 4%; preferably, lower than 3%; more preferably, lower than 2%; more preferably, lower than 1%.
  • the oral formulation does not contain benzyl benzoate.
  • the oral preparation comprises propylene glycol monocaprylate, preferably,
  • the oral preparation contains 40-60% by weight, preferably 45-55%, more preferably 50-52%, and more preferably 51.85% propylene glycol monocaprylate.
  • the oral preparation comprises PEG35 castor oil, preferably,
  • the oral preparation contains 5-10% by weight, preferably 6-9%, more preferably 7-8%, and more preferably 7.65% PEG35 castor oil.
  • the weight percentage of progesterone in the oral preparation is 10-20%; preferably, 12-18%; more preferably, 15-17.5%.
  • the oral preparation comprises propylene glycol monolaurate, preferably
  • the oral preparation comprises 15-30% by weight, preferably 20-25% propylene glycol monolaurate, more preferably, 20.8%-20.9% propylene glycol monolaurate, most preferably, 20.83% Propylene Glycol Monolaurate. .
  • the oral preparation comprises glyceryl monocaprylate, preferably, Capmul 808G
  • the oral preparation contains 5-25% by weight, preferably 8-22%, of glyceryl monocaprylate.
  • the oral preparation comprises 17- ⁇ hydroxyprogesterone caproate, propylene glycol monocaprylate, PEG35 castor oil, benzyl benzoate, and propylene glycol monolaurate or glycerol monocaprylate.
  • the oral preparation comprises 10-20% by weight of 17-alpha hydroxyprogesterone caproate, 45-55% of propylene glycol monocaprylate, 5-10% of PEG35 castor oil, 1-6% of benzene Benzyl formate, 15-25% propylene glycol monolaurate or 9-22% glyceryl monocaprylate.
  • the oral preparation is composed of 15% by weight of 17-alpha hydroxyprogesterone caproate, 51.8%-51.9% of propylene glycol monocaprylate (preferably 51.85% of propylene glycol monocaprylate), 7.65% of PEG35 castor Sesame oil, 4.6-4.7% benzyl benzoate (preferably 4.675% benzyl benzoate), 20.8-20.9% propylene glycol monolaurate (preferably 20.825% propylene glycol monolaurate).
  • the oral preparation comprises 17-alpha hydroxyprogesterone caproate, propylene glycol monocaprylate, PEG35 castor oil, and propylene glycol monolaurate.
  • the oral preparation comprises 10-20% by weight of 17-alpha hydroxyprogesterone caproate, 45-55% of propylene glycol monocaprylate, 5-10% of PEG35 castor oil, 20-30% of Propylene Glycol Monolaurate.
  • the oral preparation is composed of 15% by weight of 17-alpha hydroxyprogesterone caproate, 51.85% of propylene glycol monocaprylate, 7.65% of PEG35 castor oil, and 25.50% of propylene glycol monolaurate.
  • oral preparations of the present application are in the form of oral liquid or soft capsule, preferably in the form of soft capsule.
  • the unit preparation contains 80-150 mg of progestin, preferably 100-120 mg.
  • the oral preparation is used for contraception, or for the treatment of miscarriage, irregular menstruation, uterine bleeding, breast cancer, cytokine storm syndrome or new coronary pneumonia.
  • the present application provides the preparation method of the above-mentioned oral preparation, including the steps of weighing auxiliary materials, predissolving auxiliary materials, mixing auxiliary materials, adding progesterone, and dissolving progesterone.
  • the present application provides the use of the above-mentioned oral preparation in the preparation of drugs or reagents for contraception, treatment of miscarriage, irregular menstruation, uterine bleeding, breast cancer, cytokine storm syndrome, and new coronary pneumonia.
  • the present application provides a method for contraception, treatment of miscarriage, irregular menstruation, uterine bleeding, breast cancer, cytokine storm syndrome or new coronary pneumonia, characterized in that it includes the step of using the above-mentioned oral preparation.
  • 17- ⁇ hydroxyprogesterone caproate is also called hydroxyprogesterone caproate, 17-HPC, 17-hydroxyprogesterone caproate, 17-hydroxyprogesterone caproate, hydroxyprogesterone caproate, etc., and its CAS number It is 630-56-8; it is abbreviated as HPC in some diagrams and schemes of the embodiments.
  • the low level of benzyl benzoate described in the application means that when the preparation of the application is taken according to dosage, the intake of benzyl benzoate (or benzoic acid equivalent) meets the recommended/required level of each country, organization or textbook , preferably, when taking the preparation of the present application according to dosage, the intake of benzyl benzoate (or benzoic acid equivalent) is significantly lower than the recommended/required level of each country, organization or textbook.
  • oral dosage forms comprising the liquid formulation provided by the application are also within the protection scope of the application.
  • the composition of the present application does not exclude the inclusion of other known and unknown drugs for the treatment of related diseases, or these drugs can be administered in combination with the composition of the present application.
  • These drugs include, but are not limited to, anti-inflammatory drugs, antipyretic drugs, anti-tumor drugs, immunomodulatory drugs, etc.
  • the application improves the chemical stability of the formulation of the low benzyl benzoate oral preparation, and can enhance the clinical and commercial use range and value of the formulation.
  • the chemical stability of the formula is high, which can reduce the production cost of the product, as well as the storage and transportation cost of the product, so that the product can achieve higher economic and commercial value.
  • the safety of the low benzyl benzoate formula of the present application is also greatly improved than the original high benzyl benzoate formula.
  • the excipients used in the low benzyl benzoate formula meet the requirements for safe use, and the amount of excipients used daily also meets the standards and requirements for safe use. This also greatly increases the use range and commercial value of the low benzyl benzoate formula.
  • Fig. 1 is the actual picture of the 72-hour stability experiment of each preparation at a temperature of 5°C;
  • Fig. 2 is the actual picture of the 72-hour stability experiment of each preparation at a temperature of 12.5°C;
  • Fig. 3 is the actual picture of the 72-hour stability experiment of each formulation at a temperature of 20°C;
  • Fig. 4 is the dissolving properties of 210106, 210112, and BB formulations in FaSSIF (complete sample analysis);
  • Fig. 5 is 210106, 210112, the dissolving performance of BB preparation formula in FaSSIF (aqueous phase sample analysis);
  • Fig. 6 is the physical photograph of FaSSGF (not eating gastric juice simulated liquid) solvent sample when stripping and stirring for 120min;
  • Fig. 7 is the dissolving properties of 210106, 210112, and BB preparation formulations in FaSSGF (complete sample analysis);
  • Fig. 8 is the dissolving property (aqueous phase sample analysis) of 210106, 210112, BB preparation formula in FaSSGF;
  • Fig. 9 is the physical photo of FeSSGF (eating intestinal simulated liquid) solvent sample when stripping and stirring for 120min;
  • Figure 10 is the solubility performance of 210106, 210112, and BB formulations in FeSSIF (complete sample analysis);
  • Fig. 11 is the dissolving performance (aqueous phase sample analysis) of 210106, 210112, BB preparation formula in FeSSIF;
  • Figure 12 is a comparison of the solubility of 210106 in FeSSIF, FaSSIF and FaSSGF;
  • Figure 13 is a comparison of the solubility of 210112 in FeSSIF, FaSSIF and FaSSGF;
  • Figure 14 is a comparison of the solubility of BB formulations in FeSSIF, FaSSIF, and FaSSGF.
  • excipients were screened out for formula development, including propylene glycol monocaprylate, propylene glycol monolaurate, glyceryl monocaprylate, glyceryl oleate, and glycerol monolinoleic acid Esters, oleic acid, olive oil, PEG15 hydroxystearic acid, PEG35 castor oil, PEG40 hydrogenated castor oil, the above-mentioned 10 kinds of excipients can use the trade names listed in Table 1 Capmul 808G, Oleic acid, olive oil, The products sold may also be products of other brands, and the above-mentioned trade names are only for clear description, and are not used to limit the scope of this application.
  • 17-HPC can reach in auxiliary material propylene glycol monocaprylate, propylene glycol monolaurate, glyceryl monocaprylate, oleic acid glyceride, glycerol monolinoleate, oleic acid, PEG35 castor oil Stable dissolution, but the stable dissolution concentration in each excipient is different, see the data in the last column of Table 2 for specific values.
  • This study showed that 17-HPC could not reach a stable dissolved concentration in PEG15 hydroxystearic acid and PEG40 hydrogenated castor oil.
  • the stable dissolved concentration of 17-HPC in olive oil did not reach the meaningful dissolved concentration required for adult formulations.
  • Design formulations 210104, 210106, 210108, 210110, 210112, 210114 according to the acceptable daily intake collected in the WHO-JECFA database or provided by the supplier, as well as the possible dosage of API and preparations:
  • ADI Allowable Daily Intake (Allowable daily intake)
  • ⁇ means compliance.
  • Table 4 Contains the preferred oral formulation formulation of 17-HPC
  • the preparation method of 210106 capsule preparation is as follows:
  • the container of ELP was preheated to 50°C ⁇ 5°C until fully molten state and further homogenized before weighing.
  • the ELP (0.382 kg) will be added to the container and the complete formulation will be mixed with good agitation at 30°C ⁇ 5°C until completely dissolved.
  • Formulations stored in sealed containers will be maintained at 25°C ⁇ 5°C with gentle agitation until completely degassed (ie, a clear homogeneous solution without air bubbles).
  • the formulation will be stored at room temperature until packaged.
  • Stable means no crystalline deposits are present
  • Stable means no crystalline deposits are present
  • the experimental condition was 12.5°C for 72 hours; only the formula 106 on the far left showed no precipitation; the other three formulas had various degrees of precipitation.
  • Embodiment 4 Dissolution test
  • the dissolution apparatus is Pion micro dissolution apparatus, which is often used for preparation screening. This experiment is an evaluation of the rate of dissolution as a function of time. Under non-sink conditions, with a constant temperature of 37°C, six 250ml dissolution vessels were used at 250 rpm with a magnetic stirring device. Due to the milky white color of the dispersion, the evaluation of dissolution by UV spectroscopy (on-line analysis) is not applicable, and the solubility is tested by HPLC. The samples are divided into whole samples and aqueous phase samples. For the comparative dissolution profiles of different formulations, the same amount of API will be put into the same solvent volume: for example, 120mg (i.e. 480mg of BB formulation and 800mg of the newly developed formulation) will be added to 250mL of solvent. The sampling time points are as follows: T5 minutes , T15 minutes, T30 minutes, (T45 minutes), T60 minutes, T120 minutes.
  • FaSSIF gut simulation fluid without food
  • the average of each point in the dissolution profile is the average of two dissolution vessel tests.
  • 400 ⁇ L of solvent was sampled once and 600 ⁇ L of acetonitrile was added, and then analyzed by HPLC high-performance liquid chromatography.
  • For the aqueous phase sample take 1 portion of 1000 ⁇ L solvent sample and centrifuge at 14.8 MRPM for 20 minutes. Then take 400 ⁇ L of the supernatant aqueous phase and add 600 ⁇ L of acetonitrile, and then perform HPLC analysis. The data looks like this:
  • the concentration returned to about 100%.
  • the two newly developed formulations contained higher dissolution concentrations in the water phase, indicating that the formulations exhibited higher API water solubility, especially Formulation prototype 210106; according to the experimental results and physical stability test results, the formulation formulation prototype 210106 will be considered as the main formulation for in vivo preclinical experiments.
  • FaSSGF gastric fluid simulated without food
  • the average of each point in the dissolution profile is the average of two dissolution vessel tests.
  • 400 ⁇ L of solvent was sampled once and 600 ⁇ L of acetonitrile was added, and then analyzed by HPLC high-performance liquid chromatography.
  • For the aqueous phase sample take 1 portion of 1000 ⁇ L solvent sample and centrifuge at 14.8 MRPM for 20 minutes. Then take 400 ⁇ L of the supernatant aqueous phase and add 600 ⁇ L of acetonitrile, and then perform HPLC analysis. The data looks like this:
  • Fig. 6 is the photo of FaSSGF (do not eat gastric juice simulated solution) solvent sample when stripping and stirring for 120min. It can be seen that in the simulated gastric juice, the three formulations are all in the state of turbid suspension, indicating that most of the API has not been dissolved in the water phase. This also explains the low dissolution rate in the dissolution profile of the aqueous samples.
  • FaSSGF do not eat gastric juice simulated solution
  • the average of each point in the dissolution profile is the average of two dissolution vessel tests.
  • 400 ⁇ L of solvent was sampled once and 600 ⁇ L of acetonitrile was added, and then analyzed by HPLC high-performance liquid chromatography.
  • For the aqueous phase sample take 1 portion of 1000 ⁇ L solvent sample and centrifuge at 14.8 MRPM for 20 minutes. Then take 400 ⁇ L of the supernatant aqueous phase and add 600 ⁇ L of acetonitrile, and then perform HPLC analysis. The data looks like this:
  • Fig. 9 is a photo of FeSSGF (eating intestinal simulated fluid) solvent sample during dissolution and stirring for 120 min.
  • FeSSGF eating intestinal simulated fluid
  • the clarity of formula 106 and diazepam 112 is much higher than that of formula BB, indicating that most of the API has been dissolved in the water phase, so the turbidity will be low.
  • This also explains the much higher dissolution rates of Formulations 106 and 102 than Formulation BB in the dissolution profile of the aqueous samples.
  • the dissolution curve shows that the formulation exhibits high API water solubility, especially the formulation prototype 210106; according to the experimental results and physical stability test results, the formulation formulation prototype 210106 will be considered as the main formulation for in vivo preclinical experiments.
  • the dissolution curve also shows that the bioavailability of the new formula is likely to be higher than that of the previous BB formula. After the human body takes the new formula, the API may be more effectively absorbed by the human body than the original formula.
  • the application improves the chemical stability of the formulation of the low benzyl benzoate oral preparation, and can enhance the clinical and commercial use range and value of the formulation.
  • the chemical stability of the formula is high, which can reduce the production cost of the product, as well as the storage and transportation cost of the product, so that the product can achieve higher economic and commercial value.
  • the safety of the low benzyl benzoate formula of the present application is also greatly improved than the original high benzyl benzoate formula.
  • the excipients used in the low benzyl benzoate formula meet the requirements for safe use, and the amount of excipients used daily also meets the standards and requirements for safe use. This also greatly increases the use range and commercial value of the low benzyl benzoate formula.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种包含孕激素的口服制剂及制备方法和应用，口服制剂中不含有或仅含有重量百分比低于8%的苯甲酸苄酯。所述制剂包含17-α己酸羟孕酮、丙二醇单辛酸酯、PEG35蓖麻油、丙二醇单月桂酸酯。口服制剂在保证高安全性的情况下，提供了良好的稳定性、溶出性能和生物利用度。

Description

一种包含孕激素的新型口服制剂及制备方法和应用
相关申请的交叉引用
本申请要求在2021年11月5日提交中国专利局、申请号为202111306285.8、发明名称为“一种包含孕激素的新型口服制剂及制备方法和应用”的中国专利申请的优先权，其全部内容通过引用的方式并入本文中。
技术领域
本申请属于药剂领域，具体地，本申请提供了一种包含孕激素的新型口服制剂及制备方法和应用，该制剂中不含有或者仅含有低水平的苯甲酸苄酯。
背景技术
孕激素包括黄体酮、异炔诺酮、甲炔诺酮、17-α羟孕酮等，其在人体中有着丰富多样的生理功能，目前已将17-α羟孕酮用于避孕，治疗流产、月经不调、子宫出血、乳腺癌等疾病。除此之外，申请人还发现了17-α己酸羟孕酮有治疗细胞因子风暴综合征的作用，并已就此申请专利。
口服制剂在使用方便性和顺应性上明显优于注射等剂型，申请人先前与其他主体合作研制了17-α己酸羟孕酮口服制剂并申请了专利，该制剂有良好的口服利用度和稳定性。但该制剂以苯甲酸苄酯为主要溶剂成分，苯甲酸苄酯对人体的安全性能尚未被清楚地研究，在联合国粮农组织和世界卫生组织下的食品添加剂联合专家委员会(JECFA)的规定中，限定了苯甲酸苄酯以苯甲酸当量表示的可接受每日摄入量(ADI)5mg/kg。
上述问题使得现有17-α己酸羟孕酮口服制剂在进一步推广实用上存在障碍，因此，研制更为安全的，低或无苯甲酸苄酯的17-α己酸羟孕酮口服制剂很有必要。
发明内容
为解决上述问题，申请人在基本性质、安全性等方面筛选了大量辅料，设计了具有高安全性、良好的稳定性、溶出性能和生物利用度的口服制剂。
一方面，本申请提供了一种包含孕激素的口服制剂，其特征在于，所述口服制剂中不含有或者仅含有低水平的苯甲酸苄酯。
进一步地，所述孕激素为17-α己酸羟孕酮。
进一步地，所述口服制剂中的苯甲酸苄酯重量百分比低于8％；优选地，低于7％；更优选地，低于6％；再优选地，低于5％。
进一步地，所述口服制剂中的苯甲酸苄酯重量百分比低于4％；优选地，低于3％；更优选地，低于2％；再优选地，低于1％。
进一步地，所述口服制剂中不含有苯甲酸苄酯。
进一步地，所述口服制剂中包含丙二醇单辛酸酯，优选地，
Figure PCTCN2022125665-appb-000001
进一步地，所述口服制剂中包含重量百分数40-60％，优选45-55％，更优选50-52％，再优选51.85％的丙二醇单辛酸酯。
进一步地，所述口服制剂中包含PEG35蓖麻油，优选地，
Figure PCTCN2022125665-appb-000002
进一步地，所述口服制剂中包含重量百分数5-10％，优选6-9％，更优选7-8％，再优选7.65％的PEG35蓖麻油。
进一步地，所述口服制剂中的孕酮重量百分比为10-20％；优选地，12-18％；更优选地，15-17.5％。
进一步地，所述口服制剂中包含丙二醇单月桂酸酯，优选地
Figure PCTCN2022125665-appb-000003
进一步地，所述口服制剂中包含重量百分数15-30％，优选20-25％的丙二醇单月桂酸酯,更优选地，20.8％-20.9％的丙二醇单月桂酸酯，最优选地，20.83％的丙二醇单月桂酸酯。。
进一步地，所述口服制剂中包含甘油单辛酸酯，优选地，Capmul 808G
进一步地，所述口服制剂中包含重量百分数5-25％，优选8-22％的甘油单辛酸酯。
进一步地，所述口服制剂中包含17-α己酸羟孕酮、丙二醇单辛酸酯、PEG35蓖麻油、苯甲酸苄酯，以及丙二醇单月桂酸酯或者甘油单辛酸酯。
进一步地，所述口服制剂包含重量百分数10-20％的17-α己酸羟孕酮、45-55％的丙二醇单辛酸酯、5-10％的PEG35蓖麻油、1-6％的苯甲酸苄酯、15-25％的丙二醇单月桂酸酯或者9-22％的甘油单辛酸酯。
进一步地，所述口服制剂由重量百分数15％的17-α己酸羟孕酮、51.8％-51.9％的丙二醇单辛酸酯(优选51.85％的丙二醇单辛酸酯)、7.65％的PEG35蓖麻油、4.6-4.7％的苯甲酸苄酯(优选4.675％的苯甲酸苄酯)、20.8-20.9％的丙二醇单月桂酸酯(优选20.825％的丙二醇单月桂酸酯)组成。
或者由17.5％的17-α己酸羟孕酮、60.64％的丙二醇单辛酸酯、7.43％的PEG35蓖麻油、5.355％的苯甲酸苄酯、9.075％的甘油单辛酸酯组成；
或者由15％的17-α己酸羟孕酮、51.8％-51.9％的丙二醇单辛酸酯(优选51.85％的丙二醇单辛酸酯)、7.65％的PEG35蓖麻油、4.6-47％的苯甲酸苄酯(优选4.675％的苯甲酸苄酯)、20.8-20.9％的甘油单辛酸酯(优选20.825％的甘油单辛酸酯)组成。
进一步地，所述口服制剂中包含17-α己酸羟孕酮、丙二醇单辛酸酯、PEG35蓖麻油、丙二醇单月桂酸酯。
进一步地，所述口服制剂中包含重量百分数10-20％的17-α己酸羟孕酮、45-55％的丙二醇单辛酸酯、5-10％的PEG35蓖麻油、20-30％的丙二醇单月桂酸酯。
进一步地，所述口服制剂由重量百分数15％的17-α己酸羟孕酮、51.85％的丙二醇单辛酸酯、7.65％的PEG35蓖麻油、25.50％的丙二醇单月桂酸酯组成。
进一步地，本申请的口服制剂为口服液、软胶囊剂型，优选软胶囊剂型。
进一步地，单位制剂中包含孕激素80-150mg，优选100-120mg。
进一步地，所述口服制剂用于避孕，或者用于治疗流产、月经不调、子宫出血、乳腺癌、细胞因子风暴综合征或新冠肺炎。
另一方面，本申请提供了上述口服制剂的制备方法，包括称量辅料、预溶辅料、混合辅料、加入孕酮、溶解孕酮的步骤。
另一方面，本申请提供了上述口服制剂在制备用于避孕，治疗流产、月经不调、子宫出血、乳腺癌、细胞因子风暴综合征、新冠肺炎的药物或试剂中的用途。
另一方面，本申请提供了避孕，治疗治疗流产、月经不调、子宫出血、乳腺癌、细胞因子风暴综合征或新冠肺炎的方法，其特征在于，包括使用上述口服制剂的步骤。
本申请中17-α己酸羟孕酮也被称为己酸羟孕酮、17-HPC、17-己酸羟孕酮、17-羟己孕酮、己酸羟孕酮等，其CAS编号为630-56-8；在实施例某些图表、方案中简写为HPC。本申请中所述的低水平的苯甲酸苄酯是指按照剂量服用本申请的制剂时，苯甲酸苄酯(或苯甲酸当量)的摄入量符合各国家、组织或教科书的推荐/要求水平，优选地，照剂量服用本申请的制剂时，苯甲酸苄酯(或苯甲酸当量)的摄入量明显低于各国家、组织或教科书的推荐/要求水平。
本申请中的列举的
Figure PCTCN2022125665-appb-000004
Capmul 808G、
Figure PCTCN2022125665-appb-000005
Figure PCTCN2022125665-appb-000006
等商品名并不意味着保护范围仅为该商品，类似或同样化学组成和理化性质的产品也在本申请的保护范围之内。这方面，非限制性的例子为本申请中实施例中使用的
Figure PCTCN2022125665-appb-000007
本领域技术人员也可以根据需要和性能选用其他丙二醇单辛酸酯产品。
除了前述口服液、软胶囊剂型外，包含本申请提供的液体制剂配方的其他口服剂型也在本申请的保护范围内。
除了前述适应症，其他已知或者研究中的可用孕酮治疗的疾病也在本申请的制药用途保护范围。
根据治疗的需要，本申请的组合物中不排斥含有其他已知和未知的治疗相关疾病的药物，或者可以将这些药物与本申请的组合物联合施用。这些药物包括但不限于，抗炎药物、退热药物、抗肿瘤药 物、免疫调节药物等。
本申请提高低苯甲酸苄酯口服制剂配方的化学稳定性，能够增强该配方在临床和商业上的使用范围和使用价值。配方的化学稳定性高，即可降低产品的生产成本，也可以降低产品的贮存和运输成本，从而使产品取得更高的经济和商业价值.
本申请提高低苯甲酸苄酯口服制剂配方的生物利用度，可以降低药品的使用量，增强患者对药品使用的实用度.实验结果显示，低苯甲酸苄酯口服制剂配方在不禁食模拟肠道液体的实验中，在溶出实验水相的溶解度比原有高苯甲酸苄酯口服制剂配方高过8.8倍，显示其生物利用度可比原有的高苯甲酸苄酯口服制剂配方高过8.8倍，从而使其用药量也可以比原来的高苯甲酸苄酯配方低8.8倍，这样可以大大的增加低苯甲酸苄酯配方的临床和商业应用价值。
本申请低苯甲酸苄酯配方的安全性也比原有的高苯甲酸苄酯配方大大提高。低苯甲酸苄酯配方所使用的辅料符合安全使用要求，每日使用的辅料量也符合安全使用的标准和要求.这样也大大的增加了低苯甲酸苄酯配方药品的使用范围和商业价值。
附图说明
图1为各制剂在5℃温度下的72小时稳定性实验实物图；
图2为各制剂在12.5℃温度下的72小时稳定性实验实物图；
图3为各制剂在20℃温度下的72小时稳定性实验实物图；
图4为210106、210112、BB制剂配方在FaSSIF中的溶解性能(完整样本分析)；
图5为210106、210112、BB制剂配方在FaSSIF中的溶解性能(水相样本分析)；
图6为FaSSGF(不进食胃液模拟液)溶媒样品在溶出搅拌120min时的实物照片；
图7为210106、210112、BB制剂配方在FaSSGF中的溶解性能(完整样本分析)；
图8为210106、210112、BB制剂配方在FaSSGF中的溶解性能(水相样本分析)；
图9为FeSSGF(进食肠道模拟液)溶媒样品在溶出搅拌120min时的实物照片；
图10为210106、210112、BB制剂配方在FeSSIF中的溶解性能(完整样本分析)；
图11为210106、210112、BB制剂配方在FeSSIF中的溶解性能(水相样本分析)；
图12为210106在FeSSIF、FaSSIF、FaSSGF中的溶解性能比较；
图13为210112在FeSSIF、FaSSIF、FaSSGF中的溶解性能比较；
图14为BB配方在FeSSIF、FaSSIF、FaSSGF中的溶解性能比较。
具体实施方式
实施例1 配方的确定
通过基本物理性质、毒性、相关标准的筛选，筛选出10种辅料用于研制配方，包括丙二醇单辛酸酯、丙二醇单月桂酸酯、单辛酸甘油酯、油酸甘油酯、甘油单亚油酸酯、油酸、橄榄油、PEG15羟基硬脂酸、PEG35蓖麻油、PEG40氢化蓖麻油，上述10种辅料可以分别采用表1中所列的以商品名
Figure PCTCN2022125665-appb-000008
Capmul 808G、
Figure PCTCN2022125665-appb-000009
油酸、橄榄油、
Figure PCTCN2022125665-appb-000010
销售的产品，也可以采用其他品牌的产品，上述商品名仅是为了清楚的说明，而不是用于限制本申请的范围。
首先研究了这些辅料的溶解性能：基本结果如下表1所示：
表1 17-HPC在不同辅料中的溶解性能
Figure PCTCN2022125665-appb-000011
Figure PCTCN2022125665-appb-000012
表2中的数据表明，17-HPC在辅料丙二醇单辛酸酯、丙二醇单月桂酸酯、单辛酸甘油酯、油酸甘油酯、甘油单亚油酸酯、油酸、PEG35蓖麻油中能够达到稳定的溶解，但每种辅料中的稳定溶解浓度是不同的，具体数值参见表2最后一列数据。本研究表明17-HPC在PEG15羟基硬脂酸、PEG40氢化蓖麻油中不能达到稳定的溶解浓度。17-HPC在橄榄油中的稳定溶解浓度无法达到成人制剂所需的有意义的溶解浓度。
根据WHO-JECFA数据库中收集或根据供应商提供的可接受的每日摄入量，以及可能出现的API给药量和制剂给药量，设计配方210104、210106、210108、210110、210112、210114：
表2 辅料的基本情况
Figure PCTCN2022125665-appb-000013
表3 含有17-HPC的口服制剂配方
Figure PCTCN2022125665-appb-000014
Figure PCTCN2022125665-appb-000015
注：ADI表示每日容许摄入量(Allowable daily intake),√表示符合。
上面表格说明所选6个配方都符合安全摄入量，实验结果表明除了配方1和6，其余4个配方分散到水相时可以保持物理稳定性，没有晶型析出。所以针对这4个配方进行下面的进一步研究。
对上述配方进行筛选，得到优选的配方210106、210108、210110、210112：
表4 含有17-HPC的优选口服制剂配方
Figure PCTCN2022125665-appb-000016
实施例2 制剂的基本制备过程
通过以下步骤制备50g各种制剂：
A、在100mL的瓶中称量所需辅料(预溶)；
B、磁力搅拌下混合辅料(约250RPM、5分钟)；
C、添加称量的API(17-HPC)；
D、磁力搅拌，室温下250RPM，1小时；随后30℃温浴中250RPM，3小时；
E、溶解完成后进行检测，确保完全溶解。
210106胶囊制剂的制备方法如下：
步骤1-填充配方准备
需要将装有
Figure PCTCN2022125665-appb-000017
ELP的容器预热至50℃±5℃，直到完全熔融状态，并在称重前进一步均质。
所有填充配方制备步骤均在氮气冲洗下进行。
在容器中，将所需数量的
Figure PCTCN2022125665-appb-000018
(2.593kg)、
Figure PCTCN2022125665-appb-000019
(1.041kg)和苯甲酸苄酯(0.234kg)混合，直到在室温下均匀化。
添加所需量的17-HPC原料药(0.75kg)，并在30℃±5℃下充分搅拌直至完全溶解，以获得无任何悬浮API颗粒的澄清溶液。
所需数量的预熔化
Figure PCTCN2022125665-appb-000020
ELP(0.382kg)将被添加到容器中，而完整配方将在30℃±5℃充分搅拌下混合直至完全溶解。
储存在密封容器中的制剂将在25℃±5℃下保持温和搅拌，直至完全脱气(即无气泡的澄清均匀溶液)。配方将在室温下储存直至封装。
表5 胶囊制剂配料表
Figure PCTCN2022125665-appb-000021
实施例3 不同温度下的物理稳定性
在不同温度下观察优选配方在72小时的稳定性，结果如表5所示。
在不同温度下观察优选配方在不同时间的稳定性，结果如表6所示。
表6 各种制剂长时间(3天、2周和1个月)观察结果
Figure PCTCN2022125665-appb-000022
注：
稳定表示无结晶沉积物出现；
较不稳定表示极少量沉积物出现，例如1-3个结晶沉积物；
不稳定表示有较多结晶沉积物出现。
结果表明：所有的配方都对低温(5摄氏度)敏感，210106是唯一一种可以在12.5℃和20℃下保持稳定一个月的制剂。
对210106更长时间(3天、2周、1个月、2个月、3个月、4个月)的稳定性考察结果如表7所示：
表7 210106长时间(3天、2周、1个月、2个月、3个月、4个月)观察结果
Figure PCTCN2022125665-appb-000023
注：
稳定表示无结晶沉积物出现；
较不稳定表示极少量沉积物出现，例如1-3个结晶沉积物；
不稳定表示有较多结晶沉积物出现。
实物图如图1-3所示：
实验条件5℃，72小时：只有最左边的配方106显示没有沉淀析出；其余3个配方都有各种程度的沉淀析出。
实验条件12.5℃，72小时；只有最左边的配方106显示没有沉淀析出；其余3个配方都有各种程度的沉淀析出。
实验条件20℃，72小时：在温度升高的条件下，4个配方的物理稳定性都有所提高。配方106(左数第一个)和110(左数第三个)两个个配方都没有沉淀析出。
实施例4 溶出实验
表8 实验用高BB/苯甲酸苄酯配方
成分 浓度 毫克/胶囊
己酸羟孕酮 25％w/w(250mg/g) 120
苯甲酸苄酯 67.5％w/w 324
  7.5％w/w 36
合计   480
该配方是申请人之前研发的配方，其具有良好的物理和化学稳定性。但是因为苯甲酸苄酯含量较高，配方的相对安全性有待提高，所以开发了本专利包含的低苯甲酸苄酯配方。对于下面的溶出实验，把高苯甲酸苄酯配方(配方BB)和低苯甲酸苄酯配方(106配方和112配方)进行了平行对比。方法：
溶出仪器为Pion微量溶出仪，常用于制剂筛选用途。该实验是随时间变化进行溶解速率的评估。在非漏槽条件，37℃恒温，使用6个250毫升的溶出杯，250转/分，带磁力搅拌装置。由于分散液呈乳白色，通过紫外光谱(在线分析)评估溶解不适用，溶解度使用HPLC测试。样品分为全样品和水相样品。对于不同配方的对比溶出曲线，将在相同的溶媒体积中投入相同的API量：例如，在250mL的溶媒中加入120mg(即480mg的BB配方和800mg的新开发配方。取样时间点如下：T5分钟,T15分钟,T30分钟,(T45分钟),T60分钟,T120分钟。
FaSSIF(不进食肠道模拟液)
溶出曲线中每个点的平均值为两个溶出杯测试的平均值。完整样本为1次取样400μL溶媒并加入600μL乙腈，然后进行HPLC高效液相色谱法分析。水相样本为取1份1000μL溶媒样品进行离心，离心条件为14.8MRPM离心20分钟。然后取上层水相清液400μL并加入600μL乙腈，然后进行HPLC分析。数据如下所示：
表9 FaSSIF数据
Figure PCTCN2022125665-appb-000024
FaSSIF(不进食肠道模拟液)中210106/210112/BB制剂配方的比较(FaSSIF溶解媒介,37℃,250RPM,人工取样)结果如图4(完整样本分析)和图5(水相样本分析，14.8MRPM离心20分钟&上清液取样)所示，3个配方都可以在5min左右达到接近100％的溶出浓度。其中配方112在5min时的溶出浓度超过100％，是因为该配方在溶媒中分散较慢，在溶出杯上层取样时样品不够均匀，导致取到的样品更多的为油相，所以浓度过高。经过一段时间的溶出搅拌，浓度回到100％左右。同时根据水相溶出曲线我们发现，与原本的BB配方相比，两个新开发的制剂配方在水相中有含有较高的溶出浓度，说明该配方展现了较高的API水溶性，特别是配方原型210106；根据实验结果和物理稳定性实验结果，制剂配方原型210106将考虑作为体内临床前实验的主要配方。
FaSSGF(不进食胃液模拟液)
溶出曲线中每个点的平均值为两个溶出杯测试的平均值。完整样本为1次取样400μL溶媒并加入600μL乙腈，然后进行HPLC高效液相色谱法分析。水相样本为取1份1000μL溶媒样品进行离心，离心条件为14.8MRPM离心20分钟。然后取上层水相清液400μL并加入600μL乙腈，然后进行HPLC分析。数据如下所示：
表10 FaSSGF数据
Figure PCTCN2022125665-appb-000025
Figure PCTCN2022125665-appb-000026
图6为FaSSGF(不进食胃液模拟液)溶媒样品在溶出搅拌120min时的照片。可以看出来在胃液模拟液中，3种配方都为浑浊悬浮液状态，说明大部分API还未溶解到水相中。这也解释了水相样品溶出曲线中溶出度偏低的现象。
FaSSGF(不进食胃液模拟液)中210106/210112/BB制剂配方的比较(FaSSGF溶解媒介,37℃,250RPM,人工取样)结果如图7(完整样本分析)和图8(水相样品分析)所示，3个配方都可以在5min左右达到接近100％的溶出浓度。但是在水相的胃酸模拟液的溶出条件下，只有少量的API可以溶解到水相中来。三个配方在该胃酸模拟液溶出条件下区别不大。
FeSSIF(进食肠道模拟液)
溶出曲线中每个点的平均值为两个溶出杯测试的平均值。完整样本为1次取样400μL溶媒并加入600μL乙腈，然后进行HPLC高效液相色谱法分析。水相样本为取1份1000μL溶媒样品进行离心，离心条件为14.8MRPM离心20分钟。然后取上层水相清液400μL并加入600μL乙腈，然后进行HPLC分析。数据如下所示：
表11 FeSSIF数据
Figure PCTCN2022125665-appb-000027
Figure PCTCN2022125665-appb-000028
图9为FeSSGF(进食肠道模拟液)溶媒样品在溶出搅拌120min时的照片。我们可以看出来在肠道模拟液中，配方106安定112比配方BB澄清度高很多，说明大部分API已经溶解到水相中，所以浑浊度会偏低。这也解释了水相样品溶出曲线中配方106和102溶出度远高于配方BB的现象。
FeSSIF(进食肠道模拟液)中210106/210112/BB制剂配方的比较(FeSSIF溶解媒介,37℃,250RPM,人工取样)结果如图10(完整样本分析)和图11(水相样品分析)所示，3个配方都可以在5min左右达到接近100％的溶出浓度。同时根据水相溶出曲线我们发现，与原本的BB配方相比，两个新开发的制剂配方在水相中有较高的溶出浓度，该优势并且超过了FaSSIF(不进食模拟肠道液体)情况下的水相溶出的相对优势。该溶出曲线说明该配方展现了较高的API水溶性，特别是配方原型210106；根据实验结果和物理稳定性实验结果，制剂配方原型210106将考虑作为体内临床前实验的主要配方。该溶出曲线同时说明新配方的生物利用度很有可能比之前BB配方的生物利用度要高，人体服用新配方后，与原配方相比，API有可能会被更有效的被人体吸收。
每个待选配方的3种溶解介质中的行为比较：
对于每个单独的待选配方，我们进行了重新处理相同的数据集，以便更好的了解和比较每个配方其相应的3种生物相关介质中的溶解行为。数据如下表12-14和图12-14所示：
表12 按样品排列的溶出数据(106)
Figure PCTCN2022125665-appb-000029
Figure PCTCN2022125665-appb-000030
表13 按样品排列的溶出数据(112)
Figure PCTCN2022125665-appb-000031
表14 按样品排列的溶出数据(BB)
Figure PCTCN2022125665-appb-000032
Figure PCTCN2022125665-appb-000033
三种配方在三种介质FaSSIF(不进食肠道模拟液)、FeSSIF(进食肠道模拟液)和FaSSGF(不进食胃液模拟液)中的溶解性能比较如图12-14所示。通过对比针对同一个剂型的溶解介质,我们观察到如下现象：水相中的溶解度：FeSSIF(进食后的肠液)>FaSSIF(未进食肠液)>FaSSGF(未进食胃液)；其原因很有可能是因为肠液较胃液有较高pH，同时比胃液中有更高质量的胆汁酸盐，并且新配方中加入的表面活性剂辅料也起到了增加水中溶解度的优势，并帮助API在水相中有更好的吸收，从而可以提高新配方的生物利用度。
本申请提高低苯甲酸苄酯口服制剂配方的化学稳定性，能够增强该配方在临床和商业上的使用范围和使用价值。配方的化学稳定性高，即可降低产品的生产成本，也可以降低产品的贮存和运输成本，从而使产品取得更高的经济和商业价值.
本申请提高低苯甲酸苄酯口服制剂配方的生物利用度，可以降低药品的使用量，增强患者对药品使用的实用度.实验结果显示，低苯甲酸苄酯口服制剂配方在不禁食模拟肠道液体的实验中，在溶出实验水相的溶解度比原有高苯甲酸苄酯口服制剂配方高过8.8倍，显示其生物利用度可比原有的高苯甲酸苄酯口服制剂配方高过8.8倍，从而使其用药量也可以比原来的高苯甲酸苄酯配方低8.8倍，这样可以大大的增加低苯甲酸苄酯配方的临床和商业应用价值。
本申请低苯甲酸苄酯配方的安全性也比原有的高苯甲酸苄酯配方大大提高。低苯甲酸苄酯配方所使用的辅料符合安全使用要求，每日使用的辅料量也符合安全使用的标准和要求.这样也大大的增加了低苯甲酸苄酯配方药品的使用范围和商业价值。

Claims (26)

  1. 一种包含孕激素的新型口服制剂，其特征在于，所述口服制剂中不含有或者仅含有低水平的苯甲酸苄酯。
  2. 根据权利要求1所述的口服制剂，其中所述孕激素为17-α己酸羟孕酮。
  3. 根据权利要求1或2所述的口服制剂，其中所述口服制剂中的苯甲酸苄酯重量百分比低于8％；优选地，低于7％；更优选地，低于6％；再优选地，低于5％。
  4. 根据权利要求1-3任一项所述的口服制剂，其中所述口服制剂中的苯甲酸苄酯重量百分比低于4％；优选地，低于3％；更优选地，低于2％；再优选地，低于1％。
  5. 根据权利要求1-4任一项所述的口服制剂，其中所述口服制剂中不含有苯甲酸苄酯。
  6. 根据权利要求1-5任一项所述的口服制剂，其中，所述口服制剂中包含丙二醇单辛酸酯。
  7. 根据权利要求1-6任一项所述的口服制剂，其中所述口服制剂中包含重量百分数40-60％，优选45-55％，更优选50-52％，再优选51.8％-51.9％的丙二醇单辛酸酯，最优选51.85％的丙二醇单辛酸酯。
  8. 根据权利要求1-7任一项所述的口服制剂，其中所述口服制剂中包含PEG35蓖麻油。
  9. 根据权利要求1-8任一项所述的口服制剂，其中所述口服制剂中包含重量百分数5-10％，优选6-9％，更优选7-8％，再优选7.6％-7.7％的PEG35蓖麻油。
  10. 根据权利要求1-9任一项所述的口服制剂，其中所述口服制剂中的孕激素重量百分比为10-20％；优选地，12-18％；更优选地，15％。
  11. 根据权利要求1-10任一项所述的口服制剂，其中所述口服制剂中包含丙二醇单月桂酸酯。
  12. 根据权利要求1-11任一项所述的口服制剂，其中所述口服制剂中包含重量百分数15-30％，优选20-25％的丙二醇单月桂酸酯，更优选地，20.8％-20.9％的丙二醇单月桂酸酯，最优选地，20.825％的丙二醇单月桂酸酯。
  13. 根据权利要求1-12任一项所述的口服制剂，其中所述口服制剂中包含甘油单辛酸酯。
  14. 根据权利要求1-13任一项所述的口服制剂，其中所述口服制剂中包含重量百分数5-25％，优选8-22％的甘油单辛酸酯。
  15. 根据权利要求1-14任一项所述的口服制剂，其中所述口服制剂中包含17-α己酸羟孕酮、丙二醇单辛酸酯、PEG35蓖麻油、苯甲酸苄酯，以及丙二醇单月桂酸酯或者甘油单辛酸酯。
  16. 根据权利要求15所述的口服制剂，所述口服制剂包含重量百分数10-20％的17-α己酸羟孕酮、45-55％的丙二醇单辛酸酯、5-10％的PEG35蓖麻油、1-6％的苯甲酸苄酯、20-25％的丙二醇单月桂酸酯或者9-22％的甘油单辛酸酯。
  17. 根据权利要求16所述的口服制剂，所述口服制剂由重量百分数15％的17-α己酸羟孕酮、51.85％的丙二醇单辛酸酯、7.65％的PEG35蓖麻油、4.675％的苯甲酸苄酯、20.825％的丙二醇单月桂酸酯组成；
    或者由17.5％的17-α己酸羟孕酮、60.64％的丙二醇单辛酸酯、7.43％的PEG35蓖麻油、5.355％的苯甲酸苄酯、9.075％的甘油单辛酸酯组成；
    或者由15％的17-α己酸羟孕酮、51.85％的丙二醇单辛酸酯、7.65％的PEG35蓖麻油、4.675％的苯甲酸苄酯、20.825％的甘油单辛酸酯组成。
  18. 根据权利要求1-14任一项所述的口服制剂，其中所述口服制剂中包含17-α己酸羟孕酮、丙二醇单辛酸酯、PEG35蓖麻油、丙二醇单月桂酸酯。
  19. 根据权利要求18所述的口服制剂，其中所述口服制剂包含重量百分数10-20％的17-α己酸羟孕酮、45-55％的丙二醇单辛酸酯、5-10％的PEG35蓖麻油、20-30％的丙二醇单月桂酸酯。
  20. 根据权利要求19所述的口服制剂，其中所述口服制剂由重量百分数15％的17-α己酸羟孕酮、51.85％的丙二醇单辛酸酯、7.65％的PEG35蓖麻油、25.50％的丙二醇单月桂酸酯组成。
  21. 根据权利要求1-20任一项所述的口服制剂，其中所述口服制剂为医学上常用的剂型，包括口 服液、软胶囊剂型，优选软胶囊剂型。
  22. 根据权利要求1-21任一项所述的口服制剂，其中单位制剂中包含孕激素80-150mg，优选100-120mg。
  23. 根据权利要求1-22任一项所述的口服制剂的用途，其中所述口服制剂用于避孕，或者用于治疗流产、月经不调、子宫出血、乳腺癌、细胞因子风暴综合征或新冠肺炎。
  24. 根据权利要求1-22任一项所述的口服制剂在制备用于避孕，治疗流产、月经不调、子宫出血、乳腺癌、细胞因子风暴综合征的药物或试剂中的用途。
  25. 避孕，治疗流产、月经不调、子宫出血、乳腺癌、细胞因子风暴综合征或新冠肺炎的方法，其特征在于，包括使用根据权利要求1-22任一项所述的口服制剂的步骤。
  26. 根据权利要求1-22任一项所述的口服制剂的制备方法，包括称量辅料、预溶辅料、混合辅料、加入孕激素、溶解孕激素的步骤。
PCT/CN2022/125665 2021-11-05 2022-10-17 一种包含孕激素的新型口服制剂及制备方法和应用 WO2023078073A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111306285.8A CN116077416A (zh) 2021-11-05 2021-11-05 一种包含孕激素的新型口服制剂及制备方法和应用
CN202111306285.8 2021-11-05

Publications (1)

Publication Number Publication Date
WO2023078073A1 true WO2023078073A1 (zh) 2023-05-11

Family

ID=86210683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/125665 WO2023078073A1 (zh) 2021-11-05 2022-10-17 一种包含孕激素的新型口服制剂及制备方法和应用

Country Status (2)

Country Link
CN (1) CN116077416A (zh)
WO (1) WO2023078073A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1623550A (zh) * 2003-12-04 2005-06-08 张伟 己酸羟孕酮口服制剂和用途
CN101374500A (zh) * 2006-01-24 2009-02-25 拜耳先灵医药股份有限公司 用于口腔内使用的膜状药物剂型(膜片)
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
CN103826640A (zh) * 2011-07-28 2014-05-28 来普卡公司 包含17-羟基孕酮酯的口服组合物和相关方法
CN107847506A (zh) * 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法
US20180282366A1 (en) * 2015-09-29 2018-10-04 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
CN102415995B (zh) * 2011-12-09 2013-11-13 广东众生药业股份有限公司 一种黄体酮过饱和自微乳组合物及其制备方法
CN113559107B (zh) * 2020-04-28 2023-01-06 深圳埃格林医药有限公司 孕激素在制备抑制细胞因子风暴的药物中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1623550A (zh) * 2003-12-04 2005-06-08 张伟 己酸羟孕酮口服制剂和用途
CN101374500A (zh) * 2006-01-24 2009-02-25 拜耳先灵医药股份有限公司 用于口腔内使用的膜状药物剂型(膜片)
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
CN103826640A (zh) * 2011-07-28 2014-05-28 来普卡公司 包含17-羟基孕酮酯的口服组合物和相关方法
CN107847506A (zh) * 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法
US20180282366A1 (en) * 2015-09-29 2018-10-04 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

Also Published As

Publication number Publication date
CN116077416A (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
Buhse et al. Topical drug classification
Iradhati et al. Formulation and physical stability test of griseofulvin microemulsion gel
KR20010012363A (ko) 탁산의 전달을 위한 신규한 방법 및 조성물
EA006550B1 (ru) Фармацевтическая композиция на основе микронизированного прогестерона, способ её получения и её применение
CA2486553C (en) Ibuprofen suspension
EP3193887A1 (en) Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions
EP3943066B1 (en) Abuse deterrent formulations of amphetamine
CA2786330A1 (en) A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
CN101703468A (zh) 维生素e油纳米乳制剂与制备方法
WO2022222683A1 (zh) 一种辅酶q10微乳液及其制备方法和应用
JP2023520273A (ja) 治療化合物、製剤、およびその使用
Wollmer et al. A biopredictive In vitro approach for assessing compatibility of a novel pediatric hydrocortisone drug product within common pediatric dosing vehicles
Parakh et al. Application of factorial design approach in development and evaluation of self microemulsifying drug delivery system (SMEDDS) of mebendazole
Santoveña et al. Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration
WO2023078073A1 (zh) 一种包含孕激素的新型口服制剂及制备方法和应用
JP7301883B2 (ja) Ｈｃ－１１１９製剤及びその製造方法と使用
Sarfaraz et al. Formulation and evaluation of galantamine hydrobromide proniosome gel for Alzheimer’s disease
CN105125490A (zh) 一种氟苯尼考纳米乳及其制备方法
CN105997873A (zh) 一种水包油型特拉唑嗪纳米乳抗高血压药物
CN109953950B (zh) 一种包含普萘洛尔或其盐的纳米乳口服溶液及其制备方法
Kanoujia et al. Self Microemulsifying Drug Delivery System (SMEDDS): A Novel Approach to Improve the Therapeutic Efficacy of Orally Administered Drug
Seshadri et al. Formulation and evaluation of dapsone topical gel, 7.5% w/w
CN108853051B (zh) 一种熊去氧胆酸软胶囊及其制备方法
Shinde et al. Formulation, Characterization of Anticancer Nanoemulsion containing Trigonella foenum-graecum L. Seed oil
Ghorpade et al. FORMULATION AND EVALUATION OF SELF-NANO EMULSIFYING SYSTEM OF ORNIDAZOLE (SNEDDS) AS ANTI-BACTERIAL AGENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22889098

Country of ref document: EP

Kind code of ref document: A1